Gilead strikes again, penning $5bn deal to buy Tubulis
Gilead has signed its third acquisition deal since the start of the year, agreeing to buy ADC specialist Tubulis for $3.15bn upfront.
Kennedy changes vaccine panel charter after legal setback
A change to the ACIP charter has raised concerns of even greater political influence over the vaccine panel by HHS Secretary Kennedy.
AI giant Anthropic buys Coefficient Bio for $400m
Anthropic has continued its push into the healthcare sector by acquiring New York start-up Coefficient Bio.
Sanofi's bispecific lunsekimig has mixed readouts in phase 2
Sanofi's IL-13 and TSLP-targeting bispecific lunsekimig wins two, loses one, in readouts from its midstage clinical trials programme.
Amgen scores with new thyroid eye disease formulation
Can Amgen's subcutaneous version of Tepezza inject renewed growth into the thyroid eye disease blockbuster?
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
WOMA 2026: Steering the Future of Pharma Strategy
The WOMA Forum is not merely a conference. It's a convergence point for decision-makers
6th mRNA‑Based Therapeutics Summit
Advancing mRNA's Therapeutic Potential to Combat All Diseases
Agentic AI is Ready. Most Pharma Organizations Are Not
Axtria Ignite 2026 returns June 10–11 in Princeton, New Jersey
The Industry’s Most Comprehensive End-to-End TCE Forum
The 8th T Cell Engager Therapeutics Summit is taking place June 23–25 in San Diego, CA,
The Evolution Summit Announces May 2026 Program for Clinical...
marcus evans announces The Evolution Summit, taking place May 7-8, 2026 at The Ritz-Carlton, Fort Lauderdale, Florida.